|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Antimicrobial activity of Sapindus mukorossi and Rheum emodi extracts against H pylori: In vitro and in vivo studies显示文摘AIM: To evaluate the antibacterial activity of Sapindus mukorossi (S. mukorossi) and Rheum emodi (R. emodi). METHODS: Powders of S. mukorossi and R. emodi were extracted successively with petroleum ether, benzene, chloroform and ethanol and were concentrated in vacuum. The disk diffusion method was used for in vitro studies and in vivo studies were performed on male Wister rats. Thirty resistant clinical isolates of H pylori, as determined by their antibiotic sensitivity patterns by E-test, along with two Gram +ve (S. aureus, B. subtilis) and two Gram -ve (E. coli, P. vugaris) organisms were screened for their susceptibility patterns against these extracts. RESULTS: In our screening, all 30 resistant isolates and the other four organisms (two Gram +ve S. aureus, B. subtilis and two Gram -ve, E. coli, P. vugaris) were sensitive to the test compounds. It was found that ethanol and chloroform extracts of S. mukorossi and ethanol and benzene extracts of R. emodi inhibited H pylori at very low concentrations. In the in vitro study, the isolates showed a considerable zone of inhibition at very low concentrations (10 μg/mL) for both the extracts. In the in vivo study, the H pylori infection was cleared with minimal doses of extracts of S. mukorossi (2.5 mg/mL) and R. emodi (3.0 mg/mL) given orally for seven days. CONCLUSION: We can conclude from this study that the extracts of S. mukorossi and R. emodi inhibited the growth of pylori in vitro and, in in vivo studies, the H pylori infection cleared within seven days at very low concentrations. We also found that H pylori did not acquire resistance against these herbal extracts even after 10 consecutive passages. | Mohammed Ibrahim Aleem A Khan Santosh K Tiwari Mohammed Aejaz Habeeb MN Khaja CM Habibullah | 2006 | World Journal of Gastroenterology2006，12，44： | 46 |
| 2 | Association between cag-pathogenicity island in Helicobacter pylori isolates from peptic ulcer,gastric carcinoma,and non-ulcer dyspepsia subjects with histological changes显示文摘AIM: To investigate the presence of the cay-pathogenicity island and the associated histological damage caused by strains with complete cay-PAI and with partial deletions in correlation to the disease status.METHODS: We analyzed the complete cag-PAI of 174representative Helicobacter pylori (H pylori ) clinical isolates obtained from patients with duodenal ulcer,gastric ulcer, gastric cancer, and non-ulcer dyspepsia using eight different oligonucleotide primers viz cagA1,cagA2, cagAP1, cagAP2, cagE, cagT, LEC-1, LEC-2spanning five different loci of the whole cag-PAI by polymerase chain reaction (PCR).RESULTS: The complete screening of the genes comprising the cag-PAI showed that larger proportions of subjects with gastric ulcer (97.8%) inhabited strains with complete cag-PAI, followed by gastric cancer (85.7%),non-ulcer dyspepsia (7.1%), and duodenal ulcer (6.9%),significant differences were found in the percentagedistribution of the genes in all the clinical groups studied.It was found that strains with complete cag-PAI were able to cause severe histological damage than with the partially deleted ones.CONCLUSION: The cay-PAI is a strong virulent marker in the disease pathogenesis as it is shown that a large number of those infected with strain with complete cag-PAI had one or the other of the irreversible gastric pathologies and interestingly 18.5% of them developed gastric carcinoma. The presence of an intact cayPAI correlates with the development of more severe pathology, and such strains were found more frequently in patients with severe gastroduodenal disease. Partial deletions of the cag-PAI appear to be sufficient to render the organism less pathogenic. | Mahaboob Ali Aleem A Khan Santosh K Tiwari Niyaz Ahmed L Venkateswar Rao CM Habibullah | 2005 | World Journal of Gastroenterology2005，11，43： | 15 |
| 3 | Immune response to an indigenously developed r-Hepatitis B vaccine in mixed population: Study of an accelerated vaccination schedule显示文摘AIM: To establish the safety and efficacy of an indigenously developed r-hepatitis B vaccine using an accelerated schedule and to highlight the social awareness and commitment in preventing the spreading of hepatitis B virus infection.METHODS: The study was a multicentric, double blind,randomized (3:1) study using three doses of vaccine immunization schedule (20 μg for those above 10 years old and 10 μg for those below 10 years old) on d 0, 30and 60. One hundred and sixty-six subjects were enrolled(87 males and 76 females aged 5-35 years). The main outcome measure was assessment of immunogenicity and safety.RESULTS: A 100% seroconversion response was observed on the 30th d after the 1st injection in both the experimental groups. The sero-protection data reported a 41.2-65.6% response on the 30th d after the 1st injection and reached 100% on the 60th d. Descriptive statical analysis showed a geometric mean titer value of 13.77 mIU/mL in the test (BEVAC) group and 10.95 mIU/mL in the commercial control (ENGERIX-B) group on the 30th d after the 1st injection. The response on the 60th d showed a geometric mean titre value (GMT) of 519.84 mIU/mL in the BEVAC group and 475.46 mIU/mL in the ENGERIX-B group. On the 90th d, the antibody titer response was observed to be 2627.58 mIU/mL in the BEVAC group and 2272.72 mIU/mL in the ENGERIX-B group. Two subjects in each group experienced pains at injection site after the first vaccination. A total of six subjects in both groups experienced a solicited adverse reaction, which included pains, swelling and redness at the injection site, three subjects in the group-B had a pain at the injection site after the third dose. No other serious adverse events occurred and no dose-related local or general symptoms were observed during the study.CONCLUSION: The vaccine is safe, efficacious and immunogenic in comparison with the well documented ENGERIX-B. | A Chowdhury A Santra CM Habibullah AA Khan J Karunakaramaiah TSA Kishore AVR Raju S Lahiri | 2005 | World Journal of Gastroenterology2005，11，7： | 12 |
| 4 | Characterization of hepatic progenitors from human fetal liver using CD34 as a hepatic progenitor marker显示文摘AIM: To enrich putative hepatic progenitors from the developing human fetal liver using CD34 as a marker. METHODS: Aborted fetuses of 13-20 wk were used for the isolation of liver cells. The cells were labeled with anti CD34; a marker used for isolating progenitor population and the cells were sorted using magnetic cell sorting. The positive fractions of cells were assessed for specific hepatic markers. Further, these cells were cultured in vitro for long term investigation. RESULTS: Flow cytometric and immunocytochemical analysis for alphafetoprotein (AFP) showed that the majority of the enriched CD34 positive cells were positive for AFP. Furthermore, these enriched cells proliferated in the long term and maintained hepatic characteristics in in vitro culture. CONCLUSION: The study shows that aborted human fetal liver is a potential source for isolation of hepatic progenitors for clinical applications. The study also demonstrates that CD34 can be a good marker for the enrichment of progenitor populations. | Parveen Nyamath Ayesha Alvi Aejaz Habeeb Sanjeev Khosla Aleem A Khan CM Habibullah | 2007 | World Journal of Gastroenterology2007，13，16： | 9 |
| 5 | Human fetal hepatocyte transplantation in patients with fulminant hepatic failure显示文摘 | Habibullah CM Syed IH Qamar A | 1994 | Transplantation1994，58，： | 1 |
| 6 | Neural stem cells & supporting cells--the new therapeutic tools for the treatment of spinal cord injury显示文摘 | Paspala SA Balaji AB Nyamath P Ahmed KS Khan AA Khaja MN Narsu ML Devi YP Murthy TV Habibullah CM | | 0，，： | 1 |
| 7 | Human fetal hepatocyte transplantation in patients with fulminant hepatic failure显示文摘 | Habibullah CM Syed IH Qamar A | 1994 | Transplantation1994，58，8： | 1 |
| 8 | Modified protocol for hepatitis B virus DNA isolation and detection 显示文摘 | Khaja MN Poduri CD Habibullah CM | 2003 | Anal Biochem2003，314，： | 1 |
| 9 | Human fetal hepatocyte transplantation in patients with fullminant hepatic failure 显示文摘 | Habibullah CM | 1994 | Transplatation1994，58，8： | 1 |
| 10 | Distribution of haptoglobin phenotypes in oesophageal and gastric cancer 显示文摘 | Jayanthi M Habibullah CM Ishaq M | 1989 | J Med Genet1989，26，3： | 1 |
| 11 | The effects of the anti-allergic agent avil on abnormal scar fibroblasts显示文摘 | VENUGOPAL J ROMAKRISHNAN M HABIBULLAH CM | 1999 | Burns1999，25，： | 1 |
| 12 | Human fetal hepatocyta transplantation in patients with fulminant hepatic failure显示文摘 | Habibullah CM Syed IH Qamar A | | Transplantation0，，： | 1 |
| 13 | Human fetal hepatocyte tansplantation in patients with fulminant hepatic failure显示文摘 | Habibullah CM Syed IH Qamar A | 1994 | Transplantation1994，58，9： | 1 |
| 14 | The effect of the antiallergicagent avil on abnormal scar fibroblasts显示文摘 | Venugopal J Ramakrishnan AA Habibullah CM | 1999 | Buns1999，25，： | 1 |
| 15 | The effect of the anti-allergic agent avil on abnormal scar fibroblasts显示文摘 | Venugopal J Ramakrishnan M Habibullah CM | 1999 | Bums1999，25，3： | 1 |
| 16 | Human fetal hepatocyte transplantation in patients with fulminant hepatic failure 显示文摘 | Hepatocyte cryopreservation : is World J Gastroenterol 2010 Habibullah CM Syed IH Qamar A | 1994 | Transplantation1994，58，8： | 1 |
| 17 | Human fetal hepatocyte transplantation in patients with fulminant hepatic failure显示文摘 | Habibullah CM Syed IH Qamar A | 1994 | Transplantation1994，27，： | 1 |
| 18 | Fetal liver perfusion:an new approach显示文摘 | Habibullah CM Ibrahim HS Qamar A | 1990 | Surg Res Commun1990，8，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员